Nicorandil is an orally efficacious vasodilatory drug and antianginal agent marketed in the UK, Australia, most of Europe, India, Philippines, Japan, South Korea, and Taiwan. It is not an approved drug by FDA. It is a niacinamide derivative that induces vasodilation of arterioles and large coronary arteries by activating potassium channels. It is often used for patients with angina who remain symptomatic despite optimal treatment with other antianginal drugs . Nicorandil is a dual-action potassium channel opener that relaxes vascular smooth muscle through membrane hyperpolarization via increased transmembrane potassium conductance and increased intracellular concentration of cyclic GMP. It is shown to dilate normal and stenotic coronary arteries and reduces both ventricular preload and afterload .
Indicated for the prevention and treatment of chronic stable angina pectoris and reduction in the risk of acute coronary syndromes.
Sheba Medical Center - PPDS, Ramat Gan, Israel
City of Hope Comprehensive Cancer Center, Duarte, California, United States
UCSD Moores Cancer Center, La Jolla, California, United States
Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai, China
Florida Cancer Specialists - Sarasota, Sarasota, Florida, United States
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
University of Kentucky, Lexington, Kentucky, United States
University of Copenhagen, Copenhagen, Danmark, Denmark
CHINA, Beijing, China
Ren Ji Hospital Afflited to School of Medicine, Shanghai Jiao Tong University, ShangHai, China
Peking union medical college hospital, Beijing, China
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.